Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.17
NYSE:ABBV's Cash-to-Debt is ranked higher than
72% of the 790 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.44 vs. NYSE:ABBV: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:ABBV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.62 Max: No Debt
Current: 0.17
Equity-to-Asset 0.07
NYSE:ABBV's Equity-to-Asset is ranked lower than
96% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:ABBV: 0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:ABBV' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.07 Max: 0.74
Current: 0.07
-0.01
0.74
Interest Coverage 8.96
NYSE:ABBV's Interest Coverage is ranked lower than
73% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. NYSE:ABBV: 8.96 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 37.44 Max: No Debt
Current: 8.96
Piotroski F-Score: 6
Altman Z-Score: 2.01
Beneish M-Score: -2.41
WACC vs ROIC
10.59%
21.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 36.60
NYSE:ABBV's Operating Margin % is ranked higher than
95% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.64 vs. NYSE:ABBV: 36.60 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:ABBV' s Operating Margin % Range Over the Past 10 Years
Min: 17.09  Med: 30.91 Max: 36.6
Current: 36.6
17.09
36.6
Net Margin % 23.22
NYSE:ABBV's Net Margin % is ranked higher than
90% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.21 vs. NYSE:ABBV: 23.22 )
Ranked among companies with meaningful Net Margin % only.
NYSE:ABBV' s Net Margin % Range Over the Past 10 Years
Min: 8.89  Med: 22.86 Max: 32.62
Current: 23.22
8.89
32.62
ROE % 116.90
NYSE:ABBV's ROE % is ranked higher than
99% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.92 vs. NYSE:ABBV: 116.90 )
Ranked among companies with meaningful ROE % only.
NYSE:ABBV' s ROE % Range Over the Past 10 Years
Min: 24.85  Med: 91.09 Max: 199.32
Current: 116.9
24.85
199.32
ROA % 9.70
NYSE:ABBV's ROA % is ranked higher than
77% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NYSE:ABBV: 9.70 )
Ranked among companies with meaningful ROA % only.
NYSE:ABBV' s ROA % Range Over the Past 10 Years
Min: 6.26  Med: 14.69 Max: 39.54
Current: 9.7
6.26
39.54
ROC (Joel Greenblatt) % 332.23
NYSE:ABBV's ROC (Joel Greenblatt) % is ranked higher than
98% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.01 vs. NYSE:ABBV: 332.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:ABBV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 75.1  Med: 146.37 Max: 332.23
Current: 332.23
75.1
332.23
3-Year Revenue Growth Rate 10.30
NYSE:ABBV's 3-Year Revenue Growth Rate is ranked higher than
63% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. NYSE:ABBV: 10.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:ABBV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.7 Max: 10.3
Current: 10.3
0
10.3
3-Year EBITDA Growth Rate 15.10
NYSE:ABBV's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.50 vs. NYSE:ABBV: 15.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:ABBV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 15.1
Current: 15.1
0
15.1
3-Year EPS without NRI Growth Rate 12.30
NYSE:ABBV's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.30 vs. NYSE:ABBV: 12.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:ABBV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.2 Max: 12.3
Current: 12.3
0
12.3
GuruFocus has detected 4 Warning Signs with AbbVie Inc $NYSE:ABBV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABBV Guru Trades in Q1 2016

Lee Ainslie 43,170 sh (New)
Joel Greenblatt 645,835 sh (+216.32%)
Jim Simons 1,563,056 sh (+168.22%)
David Dreman 30,542 sh (+16.28%)
Pioneer Investments 1,261,434 sh (+9.68%)
NWQ Managers 781,850 sh (+3.64%)
Scott Black 41,959 sh (+2.85%)
Jeff Auxier 20,572 sh (+1.48%)
Larry Robbins 13,686,588 sh (+1.05%)
Mairs and Power 268,191 sh (+0.52%)
Murray Stahl 36,154 sh (+0.37%)
Robert Bruce 232,915 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,225,000 sh (unchged)
Louis Moore Bacon Sold Out
John Paulson Sold Out
Dodge & Cox 33,232 sh (-0.07%)
PRIMECAP Management 1,022,845 sh (-12.21%)
Mario Gabelli 35,460 sh (-12.66%)
Ken Fisher 743,284 sh (-20.51%)
First Pacific Advisors 56,050 sh (-25.76%)
Tom Russo 21,718 sh (-74.96%)
Paul Tudor Jones 4,100 sh (-87.55%)
» More
Q2 2016

ABBV Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 159,258 sh (New)
Stanley Druckenmiller 1,324,920 sh (New)
Joel Greenblatt 905,598 sh (+40.22%)
Lee Ainslie 50,540 sh (+17.07%)
Pioneer Investments 1,281,950 sh (+1.63%)
Jeff Auxier 20,672 sh (+0.49%)
Mairs and Power 269,153 sh (+0.36%)
Dodge & Cox 33,232 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,225,000 sh (unchged)
First Pacific Advisors Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 35,296 sh (-0.46%)
Murray Stahl 34,755 sh (-3.87%)
PRIMECAP Management 979,845 sh (-4.20%)
Scott Black 40,138 sh (-4.34%)
Ken Fisher 693,394 sh (-6.71%)
Larry Robbins 12,454,488 sh (-9.00%)
Tom Russo 17,106 sh (-21.24%)
Jim Simons 1,217,600 sh (-22.10%)
NWQ Managers 562,288 sh (-28.08%)
David Dreman 15,897 sh (-47.95%)
» More
Q3 2016

ABBV Guru Trades in Q3 2016

Paul Tudor Jones 8,900 sh (New)
Jim Simons 1,918,456 sh (+57.56%)
Murray Stahl 35,056 sh (+0.87%)
Stanley Druckenmiller 1,324,920 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
Tom Russo 17,106 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Jeff Auxier 20,622 sh (-0.24%)
Mairs and Power 266,453 sh (-1.00%)
Manning & Napier Advisors, Inc 157,543 sh (-1.08%)
Ken Fisher 684,042 sh (-1.35%)
Lee Ainslie 49,600 sh (-1.86%)
PRIMECAP Management 953,845 sh (-2.65%)
David Dreman 15,019 sh (-5.52%)
Scott Black 36,748 sh (-8.45%)
Pioneer Investments 1,130,994 sh (-11.78%)
Joel Greenblatt 684,356 sh (-24.43%)
Mario Gabelli 20,196 sh (-42.78%)
Larry Robbins 6,030,141 sh (-51.58%)
NWQ Managers 146,743 sh (-73.90%)
Eaton Vance Worldwide Health Sciences Fund 742,955 sh (-39.35%)
» More
Q4 2016

ABBV Guru Trades in Q4 2016

Richard Pzena 3,476 sh (New)
Steven Cohen 1,136,566 sh (New)
David Dreman 22,908 sh (+52.53%)
Larry Robbins 9,116,969 sh (+51.19%)
Joel Greenblatt 935,437 sh (+36.69%)
Scott Black 37,816 sh (+2.91%)
Lee Ainslie 50,920 sh (+2.66%)
Manning & Napier Advisors, Inc 160,726 sh (+2.02%)
Ken Fisher 696,569 sh (+1.83%)
Robert Bruce 232,915 sh (unchged)
Tom Russo 17,106 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
NWQ Managers Sold Out
Mario Gabelli 20,076 sh (-0.59%)
Mairs and Power 264,365 sh (-0.78%)
Murray Stahl 33,854 sh (-3.43%)
PRIMECAP Management 901,845 sh (-5.45%)
Stanley Druckenmiller 1,221,723 sh (-7.79%)
Paul Tudor Jones 4,900 sh (-44.94%)
Jim Simons 350,800 sh (-81.71%)
Pioneer Investments 112,829 sh (-90.02%)
Eaton Vance Worldwide Health Sciences Fund 690,536 sh (-7.06%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 5122
Compare:OTCPK:GLAXF, NYSE:BMY, OTCPK:BAYRY, NYSE:LLY, NYSE:SNY, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, NYSE:MRK, OTCPK:DSKYF, NYSE:NVS, OTCPK:OPHLY, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, OTCPK:MAYNF, NAS:HCM, OTCPK:VEGPF, AMEX:TXMD » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie Inc is a research-based biopharmaceutical company incorporated in Delaware on April 10, 2012. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products. It develops and markets therapies that address some of the world's complex and serious diseases. It products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. It also has a pipeline of new medicines, including more than 50 compounds or indications in clinical development across such important medical specialties as immunology, virology/liver disease, oncology, neurological diseases and women's health. The Company's products offering includes HUMIRA, IMBRUVICA, VIEKIRA, Creon, Synagis, Lupron, Synthroid, Kaletra, AndroGel, Sevoflurane, Duodopa, Dyslipidemia products, and other products. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The Company faces competition from other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics. The manufacture, marketing, sale, promotion, and distribution of AbbVie's products are subject to comprehensive government regulation.

Ratios

vs
industry
vs
history
PE Ratio 17.11
ABBV's PE Ratio is ranked higher than
80% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. ABBV: 17.11 )
Ranked among companies with meaningful PE Ratio only.
ABBV' s PE Ratio Range Over the Past 10 Years
Min: 9.85  Med: 18.79 Max: 63.37
Current: 17.11
9.85
63.37
Forward PE Ratio 11.29
ABBV's Forward PE Ratio is ranked higher than
81% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.46 vs. ABBV: 11.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.11
ABBV's PE Ratio without NRI is ranked higher than
77% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. ABBV: 17.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABBV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.85  Med: 18.79 Max: 63.37
Current: 17.11
9.85
63.37
Price-to-Owner-Earnings 19.93
ABBV's Price-to-Owner-Earnings is ranked higher than
72% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. ABBV: 19.93 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABBV' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.74  Med: 18.28 Max: 61.16
Current: 19.93
13.74
61.16
PB Ratio 21.77
ABBV's PB Ratio is ranked lower than
93% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. ABBV: 21.77 )
Ranked among companies with meaningful PB Ratio only.
ABBV' s PB Ratio Range Over the Past 10 Years
Min: 14.08  Med: 20.2 Max: 76.98
Current: 21.77
14.08
76.98
PS Ratio 3.97
ABBV's PS Ratio is ranked lower than
54% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. ABBV: 3.97 )
Ranked among companies with meaningful PS Ratio only.
ABBV' s PS Ratio Range Over the Past 10 Years
Min: 2.83  Med: 4.21 Max: 5.67
Current: 3.97
2.83
5.67
Price-to-Free-Cash-Flow 15.44
ABBV's Price-to-Free-Cash-Flow is ranked higher than
62% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. ABBV: 15.44 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABBV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.66  Med: 14.7 Max: 38.18
Current: 15.44
8.66
38.18
Price-to-Operating-Cash-Flow 14.39
ABBV's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. ABBV: 14.39 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABBV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.2  Med: 13.59 Max: 31.6
Current: 14.39
8.2
31.6
EV-to-EBIT 14.51
ABBV's EV-to-EBIT is ranked higher than
81% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. ABBV: 14.51 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.55 Max: 42.5
Current: 14.51
10.2
42.5
EV-to-EBITDA 12.80
ABBV's EV-to-EBITDA is ranked higher than
77% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. ABBV: 12.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.7 Max: 34.1
Current: 12.8
8.6
34.1
PEG Ratio 1.80
ABBV's PEG Ratio is ranked lower than
53% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. ABBV: 1.80 )
Ranked among companies with meaningful PEG Ratio only.
ABBV' s PEG Ratio Range Over the Past 10 Years
Min: 1.8  Med: 2.32 Max: 2.75
Current: 1.8
1.8
2.75
Current Ratio 1.65
ABBV's Current Ratio is ranked lower than
99.99% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. ABBV: 1.65 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.25  Med: 1.65 Max: 2.59
Current: 1.65
1.25
2.59
Quick Ratio 1.51
ABBV's Quick Ratio is ranked lower than
99.99% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. ABBV: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.51 Max: 2.43
Current: 1.51
1.1
2.43
Days Inventory 104.35
ABBV's Days Inventory is ranked higher than
53% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. ABBV: 104.35 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 89.28 Max: 115.3
Current: 104.35
35.55
115.3
Days Sales Outstanding 67.74
ABBV's Days Sales Outstanding is ranked higher than
53% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.32 vs. ABBV: 67.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.74  Med: 78.73 Max: 93.3
Current: 67.74
67.74
93.3
Days Payable 88.04
ABBV's Days Payable is ranked lower than
99.99% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. ABBV: 88.04 )
Ranked among companies with meaningful Days Payable only.
ABBV' s Days Payable Range Over the Past 10 Years
Min: 30.33  Med: 115.54 Max: 175.86
Current: 88.04
30.33
175.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.78
ABBV's Dividend Yield % is ranked higher than
88% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. ABBV: 3.78 )
Ranked among companies with meaningful Dividend Yield % only.
ABBV' s Dividend Yield % Range Over the Past 10 Years
Min: 0.85  Med: 3.04 Max: 3.96
Current: 3.78
0.85
3.96
Dividend Payout Ratio 0.63
ABBV's Dividend Payout Ratio is ranked higher than
82% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. ABBV: 0.63 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABBV' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.63  Med: 0.64 Max: 1.51
Current: 0.63
0.63
1.51
3-Year Dividend Growth Rate 12.50
ABBV's 3-Year Dividend Growth Rate is ranked higher than
58% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. ABBV: 12.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ABBV' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 12.5
Current: 12.5
0
12.5
Forward Dividend Yield % 4.12
ABBV's Forward Dividend Yield % is ranked higher than
90% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. ABBV: 4.12 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.76
ABBV's 5-Year Yield-on-Cost % is ranked higher than
74% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. ABBV: 3.76 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABBV' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.85  Med: 3.04 Max: 3.96
Current: 3.76
0.85
3.96
3-Year Average Share Buyback Ratio -0.80
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. ABBV: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.3 Max: 0
Current: -0.8
-0.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.62
ABBV's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. ABBV: 1.62 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABBV' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.6  Med: 1.63 Max: 1.63
Current: 1.62
1.6
1.63
Price-to-Median-PS-Value 0.94
ABBV's Price-to-Median-PS-Value is ranked higher than
77% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ABBV: 0.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABBV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.01 Max: 1.25
Current: 0.94
0.7
1.25
Price-to-Peter-Lynch-Fair-Value 2.68
ABBV's Price-to-Peter-Lynch-Fair-Value is ranked lower than
73% of the 168 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. ABBV: 2.68 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABBV' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 2.65  Med: 2.7 Max: 2.7
Current: 2.68
2.65
2.7
Earnings Yield (Greenblatt) % 6.89
ABBV's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. ABBV: 6.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABBV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 6.4 Max: 9.8
Current: 6.89
2.4
9.8
Forward Rate of Return (Yacktman) % 11.97
ABBV's Forward Rate of Return (Yacktman) % is ranked higher than
54% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. ABBV: 11.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABBV' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 11.8  Med: 12.9 Max: 14.5
Current: 11.97
11.8
14.5

More Statistics

Revenue (TTM) (Mil) $25,638
EPS (TTM) $ 3.63
Beta1.47
Short Percentage of Float1.92%
52-Week Range $54.01 - 68.12
Shares Outstanding (Mil)1,593.92

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 27,742 29,890 31,924
EPS ($) 5.37 6.38 7.31
EPS without NRI ($) 5.37 6.38 7.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.73%
Dividends per Share ($) 2.52 2.66 2.77
» More Articles for NYSE:ABBV

Headlines

Articles On GuruFocus.com
AbbVie Declares Quarterly Dividend Feb 21 2017 
Galapagos NV Tests Cystic Fibrosis Treatment on First Patient Feb 03 2017 
AbbVie's Hepatitis C Treatment Under FDA Review Feb 02 2017 
Is Abbott Labs or AbbVie the Better Investment? Jan 31 2017 
AbbVie to Start Study on Alzheimer's Treatment Jan 29 2017 
AbbVie Reports 4th-Quarter 2016 Results Jan 27 2017 
AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA Jan 24 2017 
Abbott Laboratories: An Undervalued Diamond in Overvalued Markets Jan 24 2017 
AbbVie Increases Price of Humira Jan 23 2017 
AbbVie Gets FDA Approval for Lymphoma Drug Jan 22 2017 

More From Other Websites
Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink Feb 24 2017
2 Dividend Aristocrats Trading At A Discount Feb 23 2017
AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink Feb 23 2017
ABBVIE INC. Financials Feb 23 2017
Questions Linger About AbbVie's AndroGel Feb 23 2017
AbbVie Declares Quarterly Dividend Feb 21 2017
AbbVie Inc (ABBV) In Share Buyback Plan For The Third Year In A Row Feb 21 2017
AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : February 21, 2017 Feb 21 2017
ABBVIE INC. Files SEC form 10-K, Annual Report Feb 17 2017
Parsabiv Is Expected to Boost Amgen’s Revenues in 2017 Feb 17 2017
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira Feb 17 2017
AbbVie Announces $5 Billion Increase to Stock Repurchase Program Feb 17 2017
NICE Rejects AbbVie’s Leukemia Drug Venclexta Feb 16 2017
UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV) Feb 16 2017
AbbVie Declares Quarterly Dividend Feb 16 2017
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone Feb 16 2017
Eli Lilly Is Great Stock to Buy Now Feb 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)